Daxor (DXR)
(Delayed Data from NSDQ)
$9.58 USD
+0.08 (0.81%)
Updated Sep 17, 2024 02:55 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
DXR 9.58 +0.08(0.81%)
Will DXR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DXR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for DXR
Newly Published Review Highlights the Pivotal Role of Daxor?s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management
Daxor announces review published in journal on BVA
Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee
Daxor receives $300K matching fund award from Launch Tennessee
Leading Central Florida Hospital Implements Daxor?s BVA-100? Blood Volume Diagnostic for Heart Failure Patient Care